Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, Messina E, Fanetti I, Puoti M, Aghemo A, Viganò P, Vinci M, Menzaghi B, Lombardi A, Pan A, Pigozzi MG, Grossi P, Lazzaroni S, Spinelli O, Invernizzi P, Maggiolo F, Terreni N, Monforte AD, Poggio PD, Taddei MT, Colombo S, Pozzoni P, Molteni C, Brocchieri A, Bhoori S, Buscarini E, Centenaro R, Mendeni M, Colombo AE, Di Marco M, Dionigi E, Bella D, Borghi M, Zuin M, Zaltron S, Noventa F, Annalisa S, Lampertico P, Fagiuoli S. D'Ambrosio R, et al. Among authors: menzaghi b. Dig Liver Dis. 2020 Feb;52(2):190-198. doi: 10.1016/j.dld.2019.11.006. Epub 2019 Dec 6. Dig Liver Dis. 2020. PMID: 31813755
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).
Menzaghi B, Ricci E, Carenzi L, Parruti G, Orofino G, Guastavigna M, Madeddu G, Maggi P, Di Biagio A, Corsi P, Penco G, De Socio G, Martinelli C, Vichi F, Celesia BM, Franzetti M, Grosso C, Molteni C, Bonfanti P, Quirino T. Menzaghi B, et al. Biomed Pharmacother. 2013 May;67(4):293-8. doi: 10.1016/j.biopha.2012.12.005. Epub 2012 Dec 26. Biomed Pharmacother. 2013. PMID: 23433852 Clinical Trial.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F. Cento V, et al. Among authors: menzaghi b. PLoS One. 2017 May 18;12(5):e0177352. doi: 10.1371/journal.pone.0177352. eCollection 2017. PLoS One. 2017. PMID: 28545127 Free PMC article. Clinical Trial.
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Ascione A, et al. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. Infection. 2018. PMID: 29808463
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Bertoli A, et al. Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y. Sci Rep. 2018. PMID: 29895871 Free PMC article. Clinical Trial.
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group. D'Ambrosio R, et al. Among authors: menzaghi b. J Hepatol. 2019 Mar;70(3):379-387. doi: 10.1016/j.jhep.2018.11.011. Epub 2018 Nov 23. J Hepatol. 2019. PMID: 30472321
94 results